XLIF
Device
NUVASIVE, INC.
Total Payments
$26.1M
Transactions
30,682
Doctors
3,351
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.0M | 2,018 | 552 |
| 2023 | $2.7M | 3,607 | 820 |
| 2022 | $3.9M | 4,037 | 811 |
| 2021 | $4.5M | 4,018 | 836 |
| 2020 | $3.8M | 2,589 | 607 |
| 2019 | $3.7M | 5,245 | 957 |
| 2018 | $3.5M | 4,687 | 907 |
| 2017 | $2.1M | 4,481 | 838 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $14.4M | 1,732 | 55.0% |
| Royalty or License | $3.0M | 101 | 11.7% |
| Unspecified | $3.0M | 825 | 11.5% |
| Travel and Lodging | $2.6M | 11,049 | 10.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $1.6M | 517 | 6.2% |
| Food and Beverage | $974,789 | 16,306 | 3.7% |
| Space rental or facility fees (teaching hospital only) | $371,639 | 55 | 1.4% |
| Grant | $28,870 | 2 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $25,775 | 4 | 0.1% |
| Education | $22,612 | 43 | 0.1% |
| Entertainment | $2,074 | 47 | 0.0% |
| Gift | $37.06 | 1 | 0.0% |
Payments by Type
General
$23.1M
29,857 transactions
Research
$3.0M
825 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| NUVA.LIB1119: A prospective, multicenter study evaluating the safety and performance of interbody implants for the treatment of patients with degenerative conditions of the thoracic and/or lumbar spine | NuVasive, Inc. | $1.0M | 1 |
| NUVA.X1801: A Prospective Multicenter Study Evaluating the Effect of Implant Material and/or Surface Structure on Progression of Fusion in XLIF?? Surgery | NuVasive, Inc. | $438,243 | 0 |
| A prospective, multicenter study evaluating the safety and performance of interbody implants for the treatment of patients with degenerative conditions of the thoracic and/or lumbar spine | Globus Medical, Inc. | $293,417 | 0 |
| A Prospective Multicenter Study Evaluating the Effect of Implant Material and/or Surface Structure on Progression of Fusion in XLIF Surgery | NuVasive, Inc. | $208,919 | 0 |
| NUVA.LIB1119: A prospective, multicenter study evaluating the safety and performance of interbody implants for the treatment of patients with degenerative conditions of the thoracic and/or lumbar spine | Globus Medical, Inc. | $199,842 | 1 |
| A Prospective Multicenter Study Evaluating the Effect of Implant Material and/or Surface Structure on Progression of Fusion in XLIF Surgery | Globus Medical, Inc. | $194,898 | 0 |
| A prospective, multicenter study evaluating the safety and performance of interbody implants for the treatment of patients with degenerative conditions of the thoracic and/or lumbar spine | NuVasive, Inc. | $132,245 | 0 |
| NUVA.X1801 A Prospective Multicenter Study Evaluating the Effect of Implant Material and/or Surface Structure on Progression of Fusion in XLIF?? Surgery | NuVasive, Inc. | $128,312 | 0 |
| NUVA.X1801 A Prospective Multicenter Study Evaluating the Effect of Implant Material andor Surface Structure on Progression of Fusion in XLIF Surgery | NuVasive, Inc. | $120,483 | 0 |
| NUVA.X1801: A Prospective Multicenter Study Evaluating the Effect of Implant Material and/or Surface Structure on Progression of Fusion in XLIF?? Surgery | Globus Medical, Inc. | $62,031 | 0 |
| A Prospective Multicenter Study Evaluating the Effect of Implant Material and/or Surface Structure on Progression of Fusion in XLIF Surgery (Enrolling by invitation) | Globus Medical, Inc. | $52,203 | 0 |
| NUVA.DEC08020: A prospective, multicenter study evaluating the safety and performance of the NuVasive?? XLIF Decade??? Plate System for the treatment of patients with degenerative conditions of the thoracic and/or lumbar spine | NuVasive, Inc. | $35,813 | 0 |
| A Prospective, Multicenter Study Evaluating the Safety and Performance of the NuVasive XLIF Decade Plate System for the Treatment of Patients With Degenerative Conditions of the Thoracic and/or Lumbar Spine | NuVasive, Inc. | $19,350 | 0 |
| NUVA.X1901: An assessment of the safety and performance of the Modulus?? 3D-printed titanium interbody implant in patients undergoing eXtreme Lateral Interbody Fusion (XLIF??) | NuVasive, Inc. | $13,800 | 1 |
| NUVA.LIB1119 A prospective, multicenter study evaluating the safety and performance of interbody implants for the treatment of patients with degenerative conditions of the thoracic and/or lumbar spine | NuVasive, Inc. | $10,950 | 0 |
| NUVA.ACP0721: A prospective, multicenter study evaluating the safety and performance of the NuVasive?? ACP System for the treatment of patients with pathologic conditions of the cervical spine | NuVasive, Inc. | $8,800 | 0 |
| NUVA.IGA1503 A Prospective Multicenter Study Evaluating the Clinical and Radiographic Outcomes of Thoracolumbar Spine Surgery When Comprehensive Sagittal Alignment Surgical Planning is Used | NuVasive, Inc. | $8,325 | 0 |
| An Assessment of the Safety and Performance of the Modulus 3D-printed Titanium Interbody Implant in Patients Undergoing eXtreme Lateral Interbody Fusion (XLIF) | Globus Medical, Inc. | $4,804 | 1 |
| NUVA.CIB0420: A prospective, multicenter study evaluating the safety and performance of interbody implants for the treatment of patients with degenerative conditions of the cervical spine | NuVasive, Inc. | $4,532 | 0 |
| An Assessment of the Safety and Performance of the Modulus 3D-printed Titanium Interbody Implant in Patients Undergoing eXtreme Lateral Interbody Fusion (XLIF) | NuVasive, Inc. | $4,040 | 0 |
Top Doctors Receiving Payments for XLIF
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Charlottesville, VA | $3.3M | 873 |
| , MD | Neurological Surgery | Tampa, FL | $2.0M | 719 |
| , M.D | Neurological Surgery | Las Vegas, NV | $1.7M | 346 |
| , M.D | Orthopaedic Surgery | Oklahoma City, OK | $1.4M | 154 |
| , M.D | Orthopaedic Surgery of the Spine | Durango, CO | $1.4M | 221 |
| Adam Kanter | Neurological Surgery | Pittsburgh, PA | $1.1M | 66 |
| , M.D | Neurological Surgery | Pittsburgh, PA | $1.0M | 52 |
| , MD | Orthopaedic Surgery | Kirkland, WA | $831,603 | 475 |
| , M.D | Orthopaedic Surgery | Lutherville Timonium, MD | $828,272 | 94 |
| , MD | Orthopaedic Surgery | Durham, NC | $694,008 | 121 |
| , MD | Orthopaedic Surgery | Charlotte, NC | $468,972 | 201 |
| , M.D | Orthopaedic Surgery of the Spine | Chicago, IL | $458,832 | 125 |
| , M.D | Orthopaedic Surgery | Scottsdale, AZ | $450,064 | 122 |
| , M.D | Orthopaedic Surgery | La Jolla, CA | $446,478 | 80 |
| , M.D | Orthopaedic Surgery | Charlottesville, VA | $373,969 | 49 |
| , M.D | Orthopaedic Surgery | Redwood City, CA | $310,570 | 483 |
| , M.D | Orthopaedic Surgery | New York, NY | $298,117 | 297 |
| , M.D | Neurological Surgery | Walla Walla, WA | $264,646 | 276 |
| , MD | Orthopaedic Surgery of the Spine | Roxbury Crossing, MA | $237,132 | 94 |
| , M.D | Orthopaedic Surgery of the Spine | Miami, FL | $203,448 | 130 |
| , MD | Neurological Surgery | Phoenix, AZ | $186,288 | 163 |
| , MD | Orthopaedic Surgery | Melbourne, FL | $176,882 | 66 |
| , MD | Orthopaedic Surgery of the Spine | New York, NY | $172,289 | 58 |
| , M.D | Neurological Surgery | Cleveland, OH | $171,834 | 138 |
| , M.D | Orthopaedic Surgery of the Spine | Los Angeles, CA | $168,540 | 222 |
Ad
Manufacturing Companies
- NuVasive, Inc. $22.0M
- NUVASIVE, INC. $2.1M
- Globus Medical, Inc. $2.0M
- Renovis Surgical Technologies, Inc. $1,350
Product Information
- Type Device
- Total Payments $26.1M
- Total Doctors 3,351
- Transactions 30,682
About XLIF
XLIF is a device associated with $26.1M in payments to 3,351 healthcare providers, recorded across 30,682 transactions in the CMS Open Payments database. The primary manufacturer is NUVASIVE, INC..
Payment data is available from 2017 to 2024. In 2024, $2.0M was paid across 2,018 transactions to 552 doctors.
The most common payment nature for XLIF is "Consulting Fee" ($14.4M, 55.0% of total).
XLIF is associated with 20 research studies, including "NUVA.LIB1119: A prospective, multicenter study evaluating the safety and performance of interbody implants for the treatment of patients with degenerative conditions of the thoracic and/or lumbar spine" ($1.0M).